Login / Register for free to get access to My MedWorm

PharmaceuticalsPharmaceuticals RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. subscribe with MyMedWormSubscribe to this data using MyMedWorm.subscribe with GoogleReaderSubscribe to this data using GoogleReader.subscribe with BloglinesSubscribe to this data using Bloglines.subscribe with MyYahooSubscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 7.

Smith and Nephew Endoscopy Announces Availability of TRUCLEAR(TM) Hysteroscopic Morcellator at the AAGL Annual Meetingemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Innovative System Allows for Efficient Removal of Intrauterine Polyps and Fibroids ANDOVER, Mass., Nov. 17 (HSMN NewsFeed) -- Smith & Nephew's (NYSE: SNN ; LSE: SN ) Endoscopy Division announced the launch of the TRUCLEAR(TM) System, an operative hyst... DevicesSmith & Nephew, TRUCLEAR System, operative hysteroscopy, morcellator
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news

Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Canceremail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Dr... Biopharmaceuticals, OncologyGenentech, Roche Group, Avastin, bevacizumab, breast cancer
Source: HSMN NewsFeed - November 17, 2009 Category: Pharmaceuticals Source Type: news

NicOx - NCX 6560 meets primary and secondary objectives in first-in-man studyemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Sophia Antipolis, France, November 13, 2009 - NicOx S.A. (NYSE Euronext Paris: COX) today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

ConsumerLab.com Finds Many Probiotics Don't Deliver Listed Ingredientsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Many probiotic supplements do not contain the number of viable organisms listed on their labels according to a new report from ConsumerLab.com. The testing organization found that at the time a probiotic is purchased it may contain as little as 10% to 58% of the amount listed on its label.
Source: Pharmaceutical Online News - November 17, 2009 Category: Pharmaceuticals Source Type: news

Invisalign(R) Education Website Aligntechinstitute.com Wins 2009 W3 Award for Creative Excellence on the Webemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
SANTA CLARA, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq:ALGN) today announced that the Company's professional education website, Aligntechinstitute.com, has received a Silver Award in the 2009 W3 Awards competition and was honored for outstanding interactive media work in the "Health Care Services" category. Aligntechinstitute.com is a dynamic, interactive website that provides Invisalign product support, instructor-led and web-based continuing education courses, and other clinical and practice resources for Invisalign practitioners.
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news

NJBIZ Honors Integra LifeSciences as One of New Jersey's Top Fifty Fastest Growing Companiesemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
PLAINSBORO, N.J., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it was honored as one of New Jersey's Top Fifty Fastest Growing Companies by NJBIZ, one of New Jersey's leading statewide business newspaper. NJBIZ revealed the list of the top fifty New Jersey businesses that have made significant contributions to the growth, strength and success of New Jersey during its award ceremony held at The Palace in Somerset Park on Monday, November 16, 2009. Integra LifeSciences Holdings Corporation (Nasdaq:IART) was ranked #10 on this year's list.
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news

Patient Portal Technologies Awarded a New Multi Year Contract With Taylor Hospitalemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
BALDWINSVILLE, N.Y., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Patient Portal Technologies, Inc. (OTCBB:PPRG) announced today that it has been awarded a five-year, million dollar plus contract from Crozer-Chester Medical Center, on behalf of its Taylor Hospital division, to provide a full range of its patient satisfaction services. Included in the service offering is management of the television and phone system, providing HealthCast, the bedside patient education platform and Instant Response, a patient response tool for non medical support.
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news

Novartis Influenza A(H1N1) 2009 vaccine US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)email this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Interim clinical data from approximately 4,000 individuals suggest that half a dose of the currently US-approved Novartis unadjuvanted Influenza A(H1N1) 2009 vaccine met immunogenicity criteria in adults and the elderly Data also show that...
Source: Drugs.com - Clinical Trials - November 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

Infinity's IPI-504 Named One of Windhover and Campbell Alliance's "Top 10 Projects to Watch" in Oncologyemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
CAMBRIDGE, Mass., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey Tong, Ph.D., vice president, corporate and product development, will present an overview of IPI-504 (retaspimycin hydrochloride), the company's intravenous heat shock protein 90 (Hsp90) chaperone inhibitor, at the Therapeutic Area Partnerships event tomorrow, November 18, 2009 at 3:30 p.m. EST. The conference, being held November 17-19, in Boston, showcases Windhover and Campbell Alliance's 2009 "Top 10 Projects to Watch" and partnership ...
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news

XOMA Appoints Jim Neal Vice President of Business Developmentemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
BERKELEY, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President, Business Development. Mr. Neal will oversee XOMA's business development strategy and lead the team to execute key licensing initiatives to build and support XOMA's proprietary therapeutic pipeline and biodefense programs, to market the company's antibody technologies and to assess commercial opportunities and develop product candidates commercially.
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news

Drug Makers Hike Prices, Lobby Hard As Reform Efforts Progressemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Drug makers are bracing for reform by raising their prices - by 9 percent in the last year, perhaps the fastest rate since 1992, The New York Times reports. This happened "even as drug makers promise to support Washington's health care overhaul by shaving $8 billion a year off the nation's drug costs after the legislation takes effect.
Source: Pharma Industry News From Medical News Today - November 17, 2009 Category: Pharmaceuticals Tags: Pharma Industry / Biotech Industry Source Type: news

Poniard Pharmaceuticals Announces Updated Positive Clinical Data From Phase 2 Trial Of Picoplatin In Colorectal Cancer And New Phase 1 Cardiac Safety Trial Resultsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ) today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC).
Source: Pharmaceutical Online News - November 17, 2009 Category: Pharmaceuticals Source Type: news

EDAP Reports Third Quarter 2009 Financial Resultsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Highlights:
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news

Higher Dose of Merck's COZAAR (Losartan Potassium Tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Studyemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) 150 mg, administered once daily, significantly reduced the risk of all-cause death or hospitalization due to heart failure compared to a lower 50 mg once daily dose of COZAAR.
Source: Pharmaceutical Online News - November 17, 2009 Category: Pharmaceuticals Source Type: news

STARLIMS Announces Third Quarter 2009 Financial Resultsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
HOLLYWOOD, Fla., Nov. 17, 2009 (GLOBE NEWSWIRE) -- STARLIMS Technologies Ltd. (Nasdaq:LIMS), a leading provider of laboratory information management systems (LIMS), today announced financial results for the third quarter of fiscal 2009 ended September 30, 2009.
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news

IRIS International's Sample Processing Division Enters Veterinary Ova and Parasite Detection Market With New Novel Sample Processing Kitemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
CHATSWORTH, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer and marketer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that its Sample Processing Division has initiated shipments of its new StatSpin(R) OvaTube(TM) System for use in veterinary hospitals, clinics and reference laboratories to process fecal samples for the detection of ova and parasites.
Source: Medical News (via PRIMEZONE) - November 17, 2009 Category: Pharmaceuticals Source Type: news

Novartis: Lower Dose of Flu Vaccine Sufficient (AP)email this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Novartis: Lower Dose of Flu Vaccine Sufficient (AP) From Associated Press (November 17, 2009) BASEL, Switzerland_Pharmaceutical maker Novartis AG said Tuesday a U.S. clinical study suggests that half a dose of its swine flu vaccine may be...
Source: Drugs.com - Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news

C.W. Brabender Instruments, Inc. Introduces The NEW Mini-Compounder 12mm Miniature Twin Screw Extruder For The Plastics And Pharmaceutical Industriesemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
C.W. Brabender Instruments, Inc. introduces the Brabender Mini-Compounder TSE 12/36, a miniature co-rotating twin screw extruder with application to the chemical as well as the pharmaceutical industry for development of new products.
Source: Pharmaceutical Online News - November 17, 2009 Category: Pharmaceuticals Source Type: news

Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies Of Apoptone (HE3235) At AACR Molecular Targets Conferenceemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC).
Source: Pharma Industry News From Medical News Today - November 17, 2009 Category: Pharmaceuticals Tags: Prostate / Prostate Cancer Source Type: news

XTEN Data From Amunix And Versartis Featured In Nature Biotechnology As A Novel Platform For Increasing Serum Half-Life Of Protein Therapeuticsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Amunix, Inc. and Versartis, Inc. announced today that the scientific journal Nature Biotechnology has published a comprehensive paper entitled "A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner." The paper (http://dx.doi.org/10.1038/nbt.
Source: Pharma Industry News From Medical News Today - November 17, 2009 Category: Pharmaceuticals Tags: Pharma Industry / Biotech Industry Source Type: news

Digital Insights: Social Media Marketing Goes to Washingtonemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
The ins and outs of the two-day FDA hearing on pharmaceutical marketing and social media.
Source: PharmaManufacturing.com - November 17, 2009 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: info

Continuous Roll Microplate Heat Sealeremail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
The TriSeal Pro from Porvair Sciences Ltd. is a new budget-priced continuous roll microplate heat sealer optimised for medium to high throughput plate sealing applications.
Source: Pharmaceutical Online News - November 17, 2009 Category: Pharmaceuticals Source Type: news

Open House For Tampa Bay Packaging Companiesemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
New England Machinery, Inc. (NEM) announced that it will be one of the 10 packaging companies hosting an Open House for interested customers the week of February 22 through 26, 2010.
Source: Pharmaceutical Online News - November 17, 2009 Category: Pharmaceuticals Source Type: news

Applications to allow Avastin to be combined with commonly used chemotherapies in advanced breast cancer submitted to FDAemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Roche announced today that Genentech, a wholly-owned member of the Roche Group, has submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the phase III AVADO study that investigated Avastin in combination with docetaxel chemotherapy. The other is based on the phase III RIBBON-1 study that investigated Avastin in combination with a taxane or anthracycline-based chemotherapy or...
Source: Roche Investor Update - November 17, 2009 Category: Pharmaceuticals Source Type: organizations

Abbott to Develop New Heart Failure Test on ARCHITECT® Immunochemistry Diagnostics Platformemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Source: Abbott.com - November 17, 2009 Category: Pharmaceuticals Source Type: organizations

Sun Pharma gets US nod for leukaemia drugemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
It has secured tentative approval from the united states food and drugs administration for the generic version of gleeven
Source: The Economic Times Healthcare and Biotech News - November 17, 2009 Category: Pharmaceuticals Source Type: news

Limited Effect Seen in Abortion Clauseemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Restrictions on abortion coverage approved in the House version of the health-care bill likely will affect the affordability of the procedure for only a small minority of women.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

Time Crunch Looms for Health Billemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Sen. Harry Reid is pressing to advance his version of the health bill this week, seeking to avoid a timing crunch that could otherwise kick the revamp until next year.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

Abortion Hurdle to Have Limited Effectemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Restrictions on abortion coverage approved in the House version of the health-care bill likely will affect the affordability of the procedure for only a small minority of women.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

Pain Device Warningemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
The FDA is demanding changes to labels on devices that deliver pain killers directly to joints after surgery, in response to numerous reports of irreversible cartilage damage.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

IPod Therapy for Alzheimer's Patientsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Evidence grows that listening to music can help stimulate seemingly lost memories and even help restore some cognitive function in stroke and dementia patients.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

New Vaccine Questionedemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
A Food and Drug Administration panel will review the safety and effectiveness of Prevnar 13, a new version of the widely used children's vaccine.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

New Study Gives B Vitamin a Boostemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Niaspan proved more effective than Merck's Zetia in reducing the accumulation of plaque in neck arteries, a marker for risk of heart attack and stroke.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

Rs 10 crore sops for 8 more AIIMSemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
In order to expedite the construction of eight new AIIMS-like institutes in the country, Union health minister Ghulam Nabi Azad announced incentives of up to Rs 10 crore for early completion of these projects.
Source: The Economic Times Healthcare and Biotech News - November 17, 2009 Category: Pharmaceuticals Source Type: news

Smokers Quit With Computer's Helpemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
New medical findings on smoking cessation, predicting heart disease, antibacterials' effects during pregnancy, breast-cancer recurrence and more.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

Council of Europe New International Convention to Combat Counterfeit Medicinesemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Source: PharmaManufacturing.com - November 17, 2009 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: info

Breast-Screening Advice Is Upendedemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
New guidelines say routine mammograms aren't necessary for women of average cancer risk in their 40s and tell physicians to abstain from teaching women how to examine their breasts for signs of cancer.
Source: WSJ.com: Health - November 17, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news

Sygnature Chemical Services and RespiVert Provide Update on Successful Discovery Collaborationemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Sygnature Chemical Services, a leading provider of medicinal and computational chemistry services to the global pharmaceutical industry, and RespiVert, a small molecule drug discovery company developing improved treatments for patients with severe respiratory disease, today provided an update on their research collaboration, first announced in January 2008. Under the terms of the agreement Sygnature have provided a comprehensive medicinal chemistry discovery platform for two of RespiVert's leading programmes aimed at identifying novel therapeutic agents for the treatment of poorly controlle...
Source: Drug Development Technology - November 17, 2009 Category: Pharmaceuticals Source Type: info

Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessionsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Source: Merck.com - Research & Development News - November 17, 2009 Category: Pharmaceuticals Source Type: news

Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technologyemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries.
Source: World Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news

BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Settingemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
AstraZeneca announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty,
Source: World Pharma News - November 17, 2009 Category: Pharmaceuticals Source Type: news

ARTES and Rhein Minapharm Continue Their Successful Product Development Collaborationemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
ARTES Biotechnology, specialised in recombinant protein production and process development from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE, jointly announced the successful production of a new target of a therapeutic protein. This was the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009. ARTES applied its proprietary Hansenula technology platform to this research collaboration and it also applied its know-how to the generation of a therape...
Source: Drug Development Technology - November 17, 2009 Category: Pharmaceuticals Source Type: info

Breast-Screening Advice Is Upendedemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
New guidelines say routine mammograms aren't necessary for women of average cancer risk in their 40s and tell physicians to abstain from teaching women how to examine their breasts for signs of cancer.
Source: WSJ.com: Health - November 16, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news